Skip to main content
SpringerLink
Log in

The Surgery of Ovarian Cancer

  • Chapter
  • First Online:
Pathology of the Ovary, Fallopian Tube and Peritoneum

Part of the book series: Essentials of Diagnostic Gynecological Pathology ((EDGP))

Abstract

Surgery has remained the mainstay of treatment for ovarian cancer despite considerable advances in chemotherapy. The findings and results of the initial laparotomy have a greater bearing on the eventual outcome than do many subsequent therapeutic decisions. Hysterectomy with bilateral salpingo-oophorectomy continues to be the most cogent therapy. Both ovaries are removed because of the frequency of bilateral synchronous tumors and the possibility of occult metastases, which may be between 6 and 43 % even in a normal-looking ovary. The uterus is removed because the uterine serosa and endometrium are also frequent sites for occult metastases, and the prevalence of synchronous carcinoma of the endometrium and ovary is relatively high.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 89.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 119.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. National Institute for Health and Clinical Excellence. NICE clinical guideline 122 – Ovarian cancer. The recognition and initial management of ovarian cancer. NHS. 2011.

    Google Scholar 

  2. Burghardt E, Girardi F, Lahousen M, Tamussino K, Stettner H. Patterns of pelvic and paraaortic lymph node involvement in ovarian cancer. Gynecol Oncol. 1991;40:103–6.

    Article  PubMed  CAS  Google Scholar 

  3. Kleppe M, Wang T, Van Gorp T, Slangen BFM, Kruse AJ, Kruitwagen RFPM. Lymph node metastasis in stages I and II ovarian cancer: a review. Gynecol Oncol. 2011;123:610–4.

    Article  PubMed  CAS  Google Scholar 

  4. Piver MS, Barlow JJ, Lele SB. Incidence of subclinical metastases in stage I and II ovarian cancer. Obstet Gynecol. 1978;52(1):100–4.

    PubMed  CAS  Google Scholar 

  5. Duska LR, Chang YC, Flynn CE, et al. Epithelial ovarian carcinoma in the reproductive age group. Cancer. 1999;85:2623–9.

    Article  PubMed  CAS  Google Scholar 

  6. Massi D, Susini T, Savino L, Boddi V, Aminni G, Cola-francesci M. Epithelial ovarian tumours in the reproductive age group: age is not an independent prognostic factor. Cancer. 1996;77:1131–6.

    Article  PubMed  CAS  Google Scholar 

  7. Plaxe SC, Braly PS, Freddo JL, McLay E, Kirmani S, Howell SB. Profiles of women aged 30 – 39 and age less than 30 with epithelial ovarian cancer. Obstet Gynecol. 1993;81(5(pt 1)):651–4.

    PubMed  CAS  Google Scholar 

  8. Smedley H, Sikora K. Age as a prognostic factor in epithelial ovarian cancer. Br J Obstet Gynaecol. 1985;92:839–42.

    Article  PubMed  CAS  Google Scholar 

  9. Swenerton KD, Hislop TG, Spinelli J, LeRiche JC, Yang N, Boyes DA. Ovarian carcinoma: a multivariate analysis of prognostic factors. Obstet Gynecol. 1985;65:264–70.

    PubMed  CAS  Google Scholar 

  10. Thigpen T, Brady MF, Omura GA, et al. Age as a prognostic factor in ovarian carcinoma. The Gynecologic Oncology Group experience. Cancer. 1993;71(2 Suppl):606–14.

    PubMed  CAS  Google Scholar 

  11. Green JA. Early ovarian cancer – time for a rethink on stage? Gynecol Oncol. 2003;90:235–7.

    Article  PubMed  Google Scholar 

  12. DiSaia PJ. Fertility-sparing treatment of patients with ovarian cancer. Compr Ther. 1990;16(11):35–42.

    PubMed  CAS  Google Scholar 

  13. Schilder JM, Thompson AM, De Priest PD, et al. Outcome of reproductive age women with stage Ia or Ic invasive epithelial ovarian cancer treated with fertility-sparing surgery. Gynecol Oncol. 2002;87:1–7.

    Article  PubMed  Google Scholar 

  14. Park J-Y, Kim D-Y, Suh D-S, Kim J-H, Kim Y-M, Kim Y-T, Nam J-H. Outcomes of fertility-sparing surgery for invasive epithelial cancer: oncologic safety and reproductive outcomes. Gynecol Oncol. 2008;110:345–53.

    Article  PubMed  Google Scholar 

  15. Wright JD, Shah M, Mathew L, Burke WM, Culhane J, Goldman N, Schiff PB, Herzog TJ. Fertility preservation in young women with epithelial ovarian cancer. Cancer. 2009;115:4118–26.

    Article  PubMed  Google Scholar 

  16. Department of Health, National Cancer Guidance Steering Group. Improving outcomes in gynaecological cancers. Cancer Service Guidance. 1999.

    Google Scholar 

  17. Schlaerth AC, Chi DS, Poynor EA, Barakat RR, Brown CL. Long-term survival after fertility-sparing surgery for epithelial ovarian cancer. Int J Gynecol Cancer. 2009;19:1199–204.

    Article  PubMed  Google Scholar 

  18. Kajiyama H, Shibata K, Mizumo M, Umezu T, Suzuki S, Nawa A, Kawai M, Nagasak T, Kikkawa F. Long-term survival of young women receiving fertility-sparing surgery for ovarian cancer in comparison with those undergoing radical surgery. Br J Cancer. 2011;105:1288–94.

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  19. Vergote I, De Brabanter J, Fyles A, et al. Prognostic importance of the degree of differentiation and cyst rupture in stage I invasive epithelial carcinoma. Lancet. 2001;357:176–82.

    Article  PubMed  CAS  Google Scholar 

  20. Weinstien D, Polishuk WZ. The role of wedge resection of the ovary as a mechanical cause for mechanical sterility. Surg Gynecol Obstet. 1975;141:417–8.

    Google Scholar 

  21. Morice P, Camatte S, El Hassan J, Pautier P, Duvillard P, Castaigne D. Clinical outcomes and fertility after conservative treatment of ovarian borderline tumours. Fertil Steril. 2001;75:92–6.

    Article  PubMed  CAS  Google Scholar 

  22. Brown C, Hyman J, Almadrones L, Curtin J, Hoskins W. Conservative surgical management of early epithelial ovarian cancer (EOC). Proc ASCO. 1995;14:766.

    Google Scholar 

  23. Munnell EW. Is conservative therapy ever justified in stage I (IA) cancer of the ovary. Am J Obstet Gynecol. 1969;103:641–53.

    PubMed  CAS  Google Scholar 

  24. Morice P, Wicart-Poque F, Rey A, El Hassan J, Pautier P, L’homme C, et al. Results of conservative treatment in epithelial ovarian carcinoma. Cancer. 2001;92:2412–8.

    Article  PubMed  CAS  Google Scholar 

  25. Zanetta G, Chiari S, Rota S, Bratina G, Maneo A, Torri V, et al. Conservative surgery for stage I ovarian carcinoma in women of childbearing age. Br J Obstet Gynaecol. 1997;104:1030–5.

    Article  PubMed  CAS  Google Scholar 

  26. Benjamin I, Morgan MA, Rubin SC. Occult bilateral involvement in stage I epithelial ovarian cancer. Gynecol Oncol. 1999;72(3):288–91.

    Article  PubMed  CAS  Google Scholar 

  27. Kottmeier HL. Surgical management – conservative surgery. In: Gentil F, Junqueria AC, editors. Ovarian cancer 2. New York: Springer; 1968.

    Google Scholar 

  28. Zaino R, Whitney C, Brady MF, et al. Simultaneously detected endometrial and ovarian carcinomas – a prospective clinicopathological study of 74 cases: a Gynecologic Oncology Group study. Gynecol Oncol. 2001;83:355–62.

    Article  PubMed  CAS  Google Scholar 

  29. ACOG classification and staging of gynecological malignancies. ACOG Technical Bulletin No 155 (May 1991). Int J Gynaecol Obstet. 1992;38:319–23.

    Google Scholar 

  30. Dos Santos SI, Swerdlow AJ. Ovarian germ cell malignancies in England: epidemiological parallels with testicular cancer. Br J Cancer. 1991;63:814–8.

    Article  Google Scholar 

  31. Wollner N, Exelby PR, Woodruff JM, et al. Malignant ovarian tumours in childhood: prognosis in relation to initial therapy. Cancer. 1976;37:1953–64.

    Article  PubMed  CAS  Google Scholar 

  32. Ablin AR, Krailo MN, Ramsay NKC, et al. Results of treatment of malignant germ cell tumours in 93 children: a report from the Children’s Cancer Group study. J Clin Oncol. 1991;9:1782–92.

    PubMed  CAS  Google Scholar 

  33. Billmire D, Vinocur C, Rescorla F, Cushing B, London W, Schlatter M, Davis M, Giller R, Lauer S, Olson T. Outcome and staging evaluation in malignant germ cell tumours of the ovary in children and adolescents: an Intergroup study. J Pediatr Surg. 2004;39:424–9.

    Article  PubMed  CAS  Google Scholar 

  34. Palenzuela G, Martin E, Meunier A, Beuzeboc P, Laurence V, Orbach D, Frappaz D. Comprehensive staging allows for excellent outcome in patients with localised malignant germ cell tumors of the ovary. Ann Surg. 2008;248(5):836–41.

    Article  PubMed  Google Scholar 

  35. Tangir J, Zelterman D, Wenging M, Schewartz PE. Reproductive function after conservative surgery for malignant germ cell tumours of the ovary. Obstet Gynecol. 2003;101:251–7.

    Article  PubMed  Google Scholar 

  36. Low JJG, Lewis CP, Crandon AJ, Hacker NF. Conservative surgery to preserve ovarian function in patients with malignant ovarian germ cell tumours. Cancer. 2000;89:391–8.

    Article  PubMed  CAS  Google Scholar 

  37. Zanetta G, Bonazzi C, Cantu MG, Binidagger S, Locatelli A, Bratini G, et al. Survival and reproductive function after treatment of malignant germ cell ovarian tumours. J Clin Oncol. 2001;19:1015–20.

    PubMed  CAS  Google Scholar 

  38. Gershenson DM. Menstrual and reproductive function after treatment with combination chemotherapy for malignant ovarian germ cell tumours. J Clin Oncol. 1988;6:270–5.

    PubMed  CAS  Google Scholar 

  39. Brewer M, Gershenson DM, Herzog C, Mitchell M, Silva E, Wharton J. Outcome and reproductive function after chemotherapy for dysgerminoma. J Clin Oncol. 1988;6:270–5.

    Google Scholar 

  40. Koonings PP, Campbell K, Mishell Jr DR, Grimes DA. Relative frequency of primary ovarian neoplasms: a 10-year review. Obstet Gynecol. 1989;74:921–6.

    PubMed  CAS  Google Scholar 

  41. Young RH, Dickerson GR, Sculloy RE. Juvenile granulosa cell tumour of the ovary. A clinicopathological analysis of 125 cases. Am J Surg Pathol. 1984;8:575–96.

    Article  PubMed  CAS  Google Scholar 

  42. Gershenson DM. Management of early ovarian cancer: germ cell and sex cord-stromal tumours. Gynecol Oncol. 1994;55:S62–72.

    Article  PubMed  CAS  Google Scholar 

  43. NCCN. Practice guidelines in oncology v2.2011. Ovarian, fallopian tube and primary peritoneal carcinomas. 2011.

    Google Scholar 

  44. Abu-Rustum NR, Restivo A, Ivy J, Soslow R, Sabbatini P, Sonoda Y, Barakat RR, Chi DS. Retroperitonealnodal metastases in primary and recurrent granulosa cell tumors of the ovary. Gynecol Oncol. 2006;103:31–4.

    Article  PubMed  Google Scholar 

  45. Brown J, Sood AK, Deavers MT, Milojevic L, Gershenson DM. Patterns of metastasis in sex cord-stromal tumours of the ovary: can routine staging lymphadenectomy be omitted? Gynecol Oncol. 2009;113:86–90.

    Article  PubMed  Google Scholar 

  46. Thrall MM, Paley P, Pizer E, Garcia R, Goff BA. Patterns of spread and recurrence of sex cord-stromal tumors of the ovary. Gynecol Oncol. 2011;122(2):242–5.

    Article  PubMed  PubMed Central  Google Scholar 

  47. Lenhard MS, Mitterer S, Kumper C, et al. Long-term follow-up after ovarian borderline tumor: relapse and survival in a large patient cohort. Eur J Obstet Gynecol Reprod Biol. 2009;145:189–94.

    Article  PubMed  Google Scholar 

  48. Trillsch F, Mahner S, Reuttzel J. Clinical management of borderline ovarian tumors. Expert Rev Anticancer Ther. 2010;10:1115–24.

    Article  PubMed  CAS  Google Scholar 

  49. Sherman ME, Mink PJ, Curtis R, et al. Survival among women with borderline ovarian tumors and ovarian carcinoma: a population-based analysis. Cancer. 2004;100:1045–52.

    Article  PubMed  Google Scholar 

  50. Skirnisdottir I, Garmo H, Wilander E, et al. Borderline ovarian tumors in Sweden 1960–2005: trends in incidence and age at diagnosis compared to ovarian cancer. Int J Cancer. 2008;123:1897–901.

    Article  PubMed  CAS  Google Scholar 

  51. Kaern J, Trope CG, Abeler VM. A retrospective study of 370 borderline tumors of the ovary treated at the Norwegian Radium Hospital from 1970 to 1982. A review of clinicopathological features and treatment modalities. Cancer. 1993;71:1810–20.

    Article  PubMed  CAS  Google Scholar 

  52. Seidman JD, Horkayne-Szakaly I, Haiba M, et al. The histologic type and stage distribution of ovarian carcinomas of surface epithelial origin. Int J Gynecol Pathol. 2004;23:41–4.

    Article  PubMed  Google Scholar 

  53. Bell DA, Weinstock MA, Scully RE. Peritoneal implants of ovarian serous borderline tumors. Histologic features and prognosis. Cancer. 1988;62:2212–22.

    Article  PubMed  CAS  Google Scholar 

  54. Tinelli R, Tinelli A, Tinelli FG, et al. Conservative surgery for borderline ovarian tumors: a review. Gynecol Oncol. 2006;100:185–91.

    Article  PubMed  Google Scholar 

  55. Kurman RJ, Trimble CL. The behaviour of serous tumors of low malignant potential: are they ever malignant? Int J Gynaecol Pathol. 1993;12:120–7.

    Article  CAS  Google Scholar 

  56. Morice P, Camatte S, Rey A, et al. Prognostic factors for patients with advanced stage borderline tumours of the ovary. Ann Oncol. 2003;14:592–8.

    Article  PubMed  CAS  Google Scholar 

  57. Oedegaard E. Ovarian carcinomas and borderline ovarian tumors – molecular markers and operative treatment. Dissertation, Faculty of Medicine, University of Oslo, 2008.

    Google Scholar 

  58. Trope CG, Davidson B, Paulsen T, et al. Diagnosis and treatment of borderline ovarian neoplasms, “the state of the art”. Eur J Gynaecol Oncol. 2009;30:471–82.

    PubMed  CAS  Google Scholar 

  59. Bazot M, Haouy D, Darai E, Cortez A, Dechoux-Vodovar S. Is MRI a useful tool to distinguish between serous and mucinous borderline ovarian tumours? Clin Radiol. 2013;68:e1–8.

    Article  PubMed  CAS  Google Scholar 

  60. Tempfer CB, Polterauer S, Bentz EK, et al. Accuracy of intraoperative frozen section analysis in borderline tumors of the ovary: a retrospective analysis of 96 cases and a review of the literature. Gynecol Oncol. 2007;107:248–52.

    Article  PubMed  Google Scholar 

  61. Trope CG, Kristensen G, Makar A. Surgery for borderline tumor of the ovary. Semin Surg Oncol. 2000;19:69–75.

    Article  PubMed  CAS  Google Scholar 

  62. Chang SJ, Ryu HS, Chang KH, et al. Prognostic significance of the micropapillary pattern in patients with serous borderline ovarian tumours. Acta Obstet Gynecol Scand. 2008;87:476–81.

    Article  PubMed  Google Scholar 

  63. Prat J, Nictolis M. Serours borderline tumors of the ovary: a long-term follow-up study of 137 cases, including 18 with a micropapillary pattern and 20 with microinvasion. Am J Surg Pathol. 2002;26:1111–28.

    Article  PubMed  Google Scholar 

  64. Seidman JD, Kurman RJ. Ovarian serous borderline tumours: a critical review of the literature with emphasis on prognostic indicators. Hum Pathol. 2000;31:539–57.

    Article  PubMed  CAS  Google Scholar 

  65. Silva EG, Gershenson DM, Malpica A, et al. The recurrence and the overall rates of ovarian serous borderline neoplasms with non invasive implants is time dependent. Am J Surg Pathol. 2006;30:551–9.

    Article  Google Scholar 

  66. Cusido M, Balaguero L, Hernandez G, et al. Results of the national survey of borderline ovarian tumors in Spain. Gynecol Oncol. 2007;104:617–22.

    Article  PubMed  Google Scholar 

  67. Longacre TA, McKenney JK, Tazelaar HD, et al. Ovarian serous tumors of low malignant potential (borderline tumors): outcome based study of 276 patients with long-term (> or =5 yr) follow up. Am J Surg Pathol. 2005;29:707–23.

    Article  PubMed  Google Scholar 

  68. Ren J, Peng Z, Yang K. A clinicopathological multivariate analysis affecting recurrence of borderline ovarian tumors. Gynecol Oncol. 2008;110:162–7.

    Article  PubMed  Google Scholar 

  69. Camatte S, Morice P, Thorbury A, et al. Impact of surgical staging in patients with macroscopic “stage I” ovarian borderline tumours: analysis of a continuous series of 101 cases. Eur J Cancer. 2004;40:1842–9.

    Article  PubMed  Google Scholar 

  70. Cadron I, Leunen K, Van Gorp T, et al. Management of borderline ovarian neoplasms. J Clin Oncol. 2007;25:2928–37.

    Article  PubMed  Google Scholar 

  71. Lim-Tan SK, Cajlgas HE, Scully RE. Ovarian cystectomy for serous borderline tumours: a follow up study of 35 cases. Obstet Gynecol. 1988;72:775–81.

    PubMed  CAS  Google Scholar 

  72. Snider DD, Stuart GC, Nation JG, Robertson DI. Evaluation of surgical staging in stage I low malignant potential ovarian tumours. Gynecol Oncol. 1991;40:129–32.

    Article  PubMed  CAS  Google Scholar 

  73. Crispens MA, Bodurka D, Deavers M, et al. Response and survival in patients with progressive or recurrent serous ovarian tumors of low malignant potential. Obstet Gynecol. 2002;99:3–10.

    Article  PubMed  Google Scholar 

  74. McGuire WP, Hoskins WJ, Brady MF, Kucera PR, Partridge EE, Look KY, Clarke-Pearson DL, Davidson M. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin: in patients with III and stage IV ovarian cancer. N Engl J Med. 1996;334:1–6.

    Article  PubMed  CAS  Google Scholar 

  75. van der Burg ML, van Lent M, Buyse MBA, Kobierska A, Colombo N, Favalli G, Lacave AJ, Nardi M, Renard J, Percorelli S. The effect of debulking surgery after induction chemotherapy on the prognosis in advanced epithelial ovarian cancer. N Engl J Med. 1995;332:629–34.

    Article  PubMed  Google Scholar 

  76. Vergote I, Trope CG, Amant F, et al. Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer. N Engl J Med. 2010;363:943–53.

    Article  PubMed  CAS  Google Scholar 

  77. Hewitt MJ, Anderson K, Hall GD, Weston M, Hutson RC, Wilkinson N, Perren TJ, Lane G, Spencer JA. Women with peritoneal carcinomatosis of unknown origin: efficacy of image-guided biopsy to determine site specific diagnosis. Br J Obstet Gynaecol. 2007;114:46–50.

    Article  CAS  Google Scholar 

  78. Hoskins WJ, McGuire WP, Brady MF, et al. The effect of diameter of largest residual disease on survival after primary cytroreductive surgery in patients with suboptimal residual epithelial ovarian carcinoma. Am J Obstet Gynecol. 1994;170:974–9.

    Article  PubMed  CAS  Google Scholar 

  79. Rouzier R, Bergzoll C, Brun J-L, Dubernard G, Selle F, Uzan S, Pomel C, Darai E. The role of lymph node resection in ovarian cancer: analysis of the surveillance epidemiology, and end results (SEER) database. BJOG. 2010;117:1451–8.

    Article  PubMed  CAS  Google Scholar 

  80. Chi DS, Eisenhauer EL, Zivanovic O, et al. Improved progression-free and overall survival in advanced ovarian cancer as a result of a change in surgical paradigm. Gynecol Oncol. 2009;114:26–31.

    Article  PubMed  Google Scholar 

  81. Peiretti M, Zanagnolo V, Aletti GD, Bocciolone L, Colombo N, Landoni F, Minig L, Biffi R, Radice D, Maggiomi A. Role of maximal primary cytoreductive surgery in patients with advanced epithelial ovarian and tubal cancer: surgical and oncological outcomes. Single institution experience. Gynecol Oncol. 2010;119:259–64.

    Article  PubMed  Google Scholar 

  82. Bristow RE, Peiretti M, Zanangnolo V, Salani R, Giuntoli II RL, Maggioni A. Transverse colectomy in ovarian cancer surgical cytoreduction: operative technique and clinical outcome. Gynecol Oncol. 2008;109:364–9.

    Article  PubMed  Google Scholar 

  83. Aletti GD, Dowdy SC, Podratz KC, Cliby WA. Surgical treatment of diaphragm disease correlates with improved survival in optimally debulked advanced stage ovarian cancer. Gynecol Oncol. 2006;100:283–7.

    Article  PubMed  Google Scholar 

  84. Wimberger P, Wehling M, Lehmann N, Kimmig R, Schmalfeldt B, Burges A, Harter P, Pfisterer J, du Boid A. Influence of residual tumor on outcome in ovarian cancer patients with stage IV disease. Ann Surg Oncol. 2010;17:1642–8.

    Article  PubMed  Google Scholar 

  85. Aletti GD, Podratz KC, Cliby WA, Gostout BS. Stage IV ovarian cancer: disease site-specific rationale for postoperative treatment. Gynecol Oncol. 2009;112:22–7.

    Article  PubMed  Google Scholar 

  86. Rafil A, Deval B, Geay J-F, Chopin N, Paoletti X, Paraiso D, Pujade-Lauraine E. Treatment of FIGO stage IV ovarian carcinoma: results of primary surgery or interval surgery after neoadjuvant chemotherapy: a retrospective study. Int J Gynecol Cancer. 2007;17:777–83.

    Article  Google Scholar 

  87. Gil-Ibanez B, Oskay-Ozcelik G, Richter R, Fotopolou C, Braicu E, Neuhaus P, Lichtenegger W, Sehouli J. Predictive factors in relapsed ovarian cancer for complete tumor remission. Anticancer Res. 2011;31:2583–7.

    PubMed  Google Scholar 

  88. Frederick PJ, Ramirez PT, Quinn L, Milam MR, Weber DM, Coleman RL, Gershenson DM, Landen CN. Preoperative factors predicting survival after secondary cytoreduction for recurrent ovarian cancer. Int J Gynecol Cancer. 2011;21:831–6.

    Article  PubMed  Google Scholar 

  89. Ford D, Easton DF, Bishop DT, et al. Risks of cancer in BRCA1-mutation carriers. Lancet. 1994;343:692–5.

    Article  PubMed  CAS  Google Scholar 

  90. Ford D, Easton DF, Stratton M, et al. Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. Am J Hum Genet. 1998;62:676–9.

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  91. Thompson D, Easton D, Breast Cancer Linkage Consortium. Variation in cancer risks, by mutation position, in BRCA2 mutation carriers. Am J Hum Genet. 2001;68:410–9.

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  92. Streuwing JP, Hartge P, Wacholder S, et al. The risk of cancer associated with specific mutations of BRCA1 and BRCA2 among Askenazi Jews. N Engl J Med. 1997;336:1401–8.

    Article  Google Scholar 

  93. Whittemore AS, Gong G, Intyre J. Prevalence and contribution of BRCA1 mutations in breast cancer and ovarian cancer: results from three US population-based case–control studies of ovarian cancer. Am J Hum Genet. 1997;60:496–504.

    PubMed  CAS  PubMed Central  Google Scholar 

  94. Amos CI, Shaw GL, Tucker MA, et al. Age at onset for familial epithelial ovarian cancer. JAMA. 1992;286:1896–9.

    Article  Google Scholar 

  95. Lynch HT, Watson P, Lynch JF, et al. Hereditary ovarian cancer: heterogeneity in age at onset. Cancer. 1993;71:573–81.

    Article  PubMed  CAS  Google Scholar 

  96. Houlston RS, Hampson J, Collins WP, et al. Correlation in ages at death from familial ovarian cancer among sisters. Gynecol Oncol. 1992;47:253–4.

    Article  PubMed  CAS  Google Scholar 

  97. NIH Consensus Development Panel on Ovarian Cancer. Ovarian cancer: screening, treatment and follow up. JAMA. 1995;273:491–7.

    Article  Google Scholar 

  98. Eltabbakh GH, Piver MS, Hempling RE, et al. Laparoscopic management of women with a family history of ovarian cancer. J Surg Oncol. 1999;72:9–13.

    Article  PubMed  CAS  Google Scholar 

  99. Morice P, Pautier P, Mercier S, et al. Laparoscopic prophylactic oophorectomy in women with inherited risk of ovarian cancer. Eur J Gynaecol Oncol. 1999;20:202–4.

    PubMed  CAS  Google Scholar 

  100. Colgan TJ, Murphy J, Cole DE, et al. Occult carcinoma in prophylactic oophorectomy specimens: prevalence and association with BRCA germline mutations. Am J Surg Pathol. 2001;25:1283–9.

    Article  PubMed  CAS  Google Scholar 

  101. Rozario D, Brown I, Fung MF, et al. Is incidental prophylactic oophorectomy an acceptable means to reduce the incidence of ovarian cancer? Am J Surg. 1997;173:495–8.

    Article  PubMed  CAS  Google Scholar 

  102. Kurman RJ, Shih I-M. The origin and pathogenesis of epithelial ovarian cancer: a proposed unifying theory. Am J Surg Pathol. 2010;34:433–43.

    Article  PubMed  PubMed Central  Google Scholar 

  103. Visvanathan K, Vang R, Shaw P, Gross A, Soslow R, Parkash V, Shih L-M, Kurman RJ. Diagnosis of serous tubal intraepithelial carcinoma based on morphologic and immunohistochemical features: a reproducibility study. Am J Surg Pathol. 2011;35:1766–75.

    Article  PubMed  Google Scholar 

  104. Anderson CK, Wallace S, Guiahi M, Sheeder J, Behbakht K, Spillman M. Risk-reducing salpingectomy as preventative strategy for pelvic serous cancer. Int J Gynecol Cancer. 2013;23:417–21.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Gynaecological Oncology, Guy’s & St Thomas Hospitals, Westminster Bridge Road, London, SE1 7EH, UK

    Geoffrey Lane MB, BS, MD, FRCOG

Authors
  1. Geoffrey Lane MB, BS, MD, FRCOG
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Geoffrey Lane MB, BS, MD, FRCOG .

Editor information

Editors and Affiliations

  1. Department of Histopathology, Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom

    Nafisa Wilkinson

Rights and permissions

Reprints and permissions

Copyright information

© 2014 Springer-Verlag London

About this chapter

Cite this chapter

Lane, G. (2014). The Surgery of Ovarian Cancer. In: Wilkinson, N. (eds) Pathology of the Ovary, Fallopian Tube and Peritoneum. Essentials of Diagnostic Gynecological Pathology. Springer, London. https://doi.org/10.1007/978-1-4471-2942-4_3

Download citation

  • DOI: https://doi.org/10.1007/978-1-4471-2942-4_3

  • Published:

  • Publisher Name: Springer, London

  • Print ISBN: 978-1-4471-2941-7

  • Online ISBN: 978-1-4471-2942-4

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation